Free Trial

Feedback (FDBK) Competitors

GBX 60.50
0.00 (0.00%)
(As of 07/26/2024 ET)

FDBK vs. RENX, COG, INHC, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS

Should you be buying Feedback stock or one of its competitors? The main competitors of Feedback include Renalytix (RENX), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.

Feedback vs.

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Feedback has higher earnings, but lower revenue than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£1.02M7.91-£3.49M-£0.26-232.69
Renalytix£2.41M8.26-£41.85M-£0.30-45.00

Feedback has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

52.8% of Feedback shares are held by institutional investors. Comparatively, 31.0% of Renalytix shares are held by institutional investors. 11.0% of Feedback shares are held by insiders. Comparatively, 35.7% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Feedback's return on equity of -32.67% beat Renalytix's return on equity.

Company Net Margins Return on Equity Return on Assets
FeedbackN/A -32.67% -21.47%
Renalytix N/A -651.40%-88.32%

Feedback received 142 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 67.07% of users gave Feedback an outperform vote.

CompanyUnderperformOutperform
FeedbackOutperform Votes
165
67.07%
Underperform Votes
81
32.93%
RenalytixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

In the previous week, Feedback's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Renalytix Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Feedback
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Feedback and Renalytix tied by winning 6 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDBK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£8.07M£204.13M£5.31B£1.57B
Dividend Yield4.56%6.59%2.72%8.65%
P/E Ratio-232.69684.49152.081,851.73
Price / Sales7.91590.262,071.74312,118.10
Price / Cash1.1238.9335.8927.71
Price / Book0.905.014.952.73
Net Income-£3.49M-£5.96M£112.29M£176.67M
7 Day PerformanceN/A0.94%2.73%0.04%
1 Month Performance-19.33%-0.92%6.97%1.60%
1 Year Performance-34.59%-11.05%11.22%93.09%

Feedback Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENX
Renalytix
0 of 5 stars
0.00 / 5 stars
GBX 13
flat
N/A-88.3%£19.18M£2.41M-43.33102Gap Up
COG
Cambridge Cognition
0 of 5 stars
0.00 / 5 stars
GBX 44.50
+2.3%
N/A-54.9%£15.64M£12.77M-445.0080News Coverage
Gap Down
INHC
Induction Healthcare Group
0 of 5 stars
0.00 / 5 stars
GBX 10
flat
N/A-50.5%£9.24M£11.82M-66.6783News Coverage
IQAI
IQ-AI
0 of 5 stars
0.00 / 5 stars
GBX 1.25
+10.6%
N/A-54.6%£2.77M£538,190.00-13.676News Coverage
TRLS
Trellus Health
0 of 5 stars
0.00 / 5 stars
GBX 1.55
flat
N/A-69.4%£2.50M£35,000.00-51.6731Gap Up
DVRG
DeepVerge
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£1.14M£12.41M-15.0073News Coverage
SENS
Sensyne Health
0 of 5 stars
0.00 / 5 stars
N/AN/A+0.0%£583,000.00£7.81M-0.0270Positive News
Gap Down
EMIS
EMIS Group
0 of 5 stars
0.00 / 5 stars
GBX 1,920
flat
N/A+32.6%£1.23B£176.86M4,085.111,560
CRW
Craneware
1.1034 of 5 stars
1.10 / 5 stars
GBX 2,470
+0.8%
GBX 2,700
+9.3%
+57.6%£872.40M£180.56M11,761.90734News Coverage
INS
Instem
0 of 5 stars
0.00 / 5 stars
GBX 830
flat
N/A+36.1%£199.62M£61.63M5,928.57500

Related Companies and Tools

This page (LON:FDBK) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners